-

Globe Life Inc. (GL) Shareholder Alert: Robbins LLP Reminds Investors of its Investigation of the Officers and Directors of Globe Life Inc.

SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP is investigating Globe Life Inc. (NYSE: GL) to determine whether certain Globe Life officers and directors violated securities laws and breached fiduciary duties to shareholders in connection with allegations that the Company's agents engaged in a pattern of unchecked sexual assault and harassment. Globe Life Inc., through its subsidiaries, provides various life and supplemental health insurance products, and annuities to lower middle to middle income households in the United States. It's largest subsidiary is American Income Life (AIL).

If you would like more information about our investigation of Globe Life Inc.'s misconduct submit a form, email Aaron Dumas, Jr., or give us a call at (800) 350-6003.

Globe Life Inc.'s (GL) Subsidiary is the Subject of a Lawsuit Alleging Sexual Assault and Harassment

According to an Insider article published in February 2023, AIL is the subject of a lawsuit filed by a female agent against AIL and her male managers. According to the article, female agents were the subject of sexual harassment, and aggressive, violent, and misogynistic behavior. They witnessed the open use of cocaine, steroids, male enhancement drugs, and other controlled substances. The article also details customer abuses and fraud. Top managers at AIL were allegedly aware of allegations of inappropriate sexual misconduct and drug abuse as far back as 2015, when a claim of misbehavior by top managers was escalated to AIL senior management. The article not only details explicit instances of misconduct by its star agents, but also references inappropriate conduct by AIL's senior executives.

Globe Life Inc. (GL) shareholders have legal options. If you own shares of Globe Life Inc., contact us for more information about your rights.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

Contact us to learn more:

Aaron Dumas, Jr.
(800) 350-6003
adumas@robbinsllp.com
Shareholder Information Form

About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. To be notified if a class action against Globe Life Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Aaron Dumas, Jr.
Robbins LLP
5060 Shoreham Pl., Ste. 300
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Robbins LLP

NYSE:GL

Release Summary
Globe Life Inc.'s (GL) Subsidiary is the Subject of a Lawsuit Alleging Sexual Assault and Harassment
Release Versions
$Cashtags

Contacts

Aaron Dumas, Jr.
Robbins LLP
5060 Shoreham Pl., Ste. 300
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Social Media Profiles
More News From Robbins LLP

Investor Notice: Robbins LLP Informs Investors of the Concorde International Group, Ltd. Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Concorde International Group, Ltd. (NASDAQ: CIGL) securities between April 21, 2025 and July 14, 2025. Concorde claims to be "an integrated security services providers that combines physical manpower and innovative technology to deliver effective security solutions." For more information, submit a form, email attorney Aaron Dumas, Jr., or give...

REGENXBIO, Inc. Stockholders Should Contact Robbins LLP for Information About Leading the RGNX Class Action

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired REGENXBIO, Inc. (NASDAQ: RGNX) securities between February 9, 2022 and January 27, 2026. REGENXBIO is a clinical-stage biotechnology company providing gene therapies that deliver functional genes to cells with genetic defects in the United States. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800)...

Investor Notice: Robbins LLP Informs Investors of the Gemini Space Station, Inc. Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Gemini Space Station, Inc. (NASDAQ: GEMI) Class A common stock pursuant and/or traceable to the Company's September 12, 2025 initial public offering ("IPO"), and/or Gemini Space Station, Inc. securities between September 12, 2025 and February 17, 2026. Gemini was founded to develop and operate a cryptocurrency platform. For more information, s...
Back to Newsroom